Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

, ABUS

Arbutus Biopharma

$2.65

-0.05 (-1.85%)

10:55
11/30/16
11/30
10:55
11/30/16
10:55

Arrowhead clinical programs halt seen as boost for small-cap peer Arbutus

Shares of Arrowhead Pharmaceuticals (ARWR) are plunging after the company announced that it is stopping the development of all of its drugs currently being tested on humans due to a setback in the drug-delivery technology. Coming only three weeks after the Food and Drug Administration placed its lead asset for hepatitis B virus on clinical hold, the news sparked several rating downgrades by Wall Street analysts. Additionally, Chardan upgraded Arbutus Biopharma (ABUS) to Buy as the firm views the news as a positive for Arrowhead's competitor. CLINICAL PROGRAMS DISCONTINUED: Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle. Both ARC-520 and ARC-521 were aimed at hepatitis B, while ARC-AAT was intended to fight Alpha-1 antitrypsin deficiency, a rare and hereditary illness that can lead to cirrhosis or cancer. Additionally, the company announced that it is reducing its workforce by approximately 30%, while "maintaining full resourcing necessary to support current and potential future partner-based programs and Arrowhead's burgeoning pipeline." ANALYSTS MOVE TO THE SIDELINES: Piper Jaffray analyst Edward Tenthoff downgraded Arrowhead to Neutral from Overweight after the company discontinued its three clinical RNAi candidates, a decision that was based on the FDA clinical hold on ARC-520 due to deaths in an ongoing non-human primate study of high doses of EX1 delivery vehicle. The analyst noted that this was a "negative surprise," and lowered his price target on the shares to $2 from $10. Tenthoff was not the only analyst moving to the sidelines after the program halt announcement. His peer at Cantor also downgraded Arrowhead to Hold from Buy, citing similar reasons. Analyst Elemer Piros told investors in a note of his own that the company is going to focus on its subcutaneously delivered candidates, which are still in early stages of development and lack visibility. He also lowered his price target on the shares to $1 from $15. Meanwhile, William Blair analyst Katherine Xu also downgraded Arrowhead to Market Perform from Outperform, and lowered her price target on the shares to $2 from $12. While the company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, Xu pointed out that she estimates these programs to be at least one to two years away from entering the clinic. HALT POSITIVE FOR COMPETITOR: Research firm Chardan downgraded Arrowhead to Neutral, while upgrading its competitor Arbutus to Buy. Analyst Madhu Kumar told investors that he now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Moreover, the analyst believes that Arrowhead's discontinuations, which are specific to the dynamic polyconjugate platform, should have minimal read-across to Arbutus and its competing assets such as ARB-1467 and ARB-1740, which do not use the same technology. PRICE ACTION: In morning action, shares of Arrowhead have dropped over 64% to $1.57, while Arbutus' stock has gained over 14% to $3.03 per share.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

ABUS

Arbutus Biopharma

$2.65

-0.05 (-1.85%)

  • 30

    Nov

  • 06

    Dec

ARWR Arrowhead
$4.39

-0.07 (-1.57%)

11/30/16
WBLR
11/30/16
DOWNGRADE
WBLR
Market Perform
Arrowhead downgraded to Market Perform from Outperform at William Blair
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded on competitor withdrawal at Chardan
As noted earlier, Chardan upgraded Arbutus (ABUS) to Buy from Neutral. Analyst Gbola Amusa upgraded the stock after Arrowhead (ARWR) announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT. The analyst now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Amusa does not expect Arbutus' treatments to cause the same safety problems as those of Arrowhead. Amusa is upbeat on Arbutus' lead asset, ARB-1467. Target to $4 from $3.
11/30/16
11/30/16
DOWNGRADE
Target $2

Market Perform
Arrowhead downgraded at William Blair after clinical programs discontinued
As previously reported, William Blair analyst Katherine Xu downgraded Arrowhead to Market Perform from Outperform after the company announced that it would discontinue all of its current clinical-stage programs three weeks after the FDA placed lead asset ARC-520 for hepatitis B virus on clinical hold. The company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, though Xu estimates these programs are at least one to two years away from entering the clinic. Xu cut her price target on Arrowhead shares to $2 from $12.
11/30/16
11/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 2. Arrowhead (ARWR) was downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Buy at Chardan, to Hold from Buy at Cantor, and to Market Perform from Outperform at William Blair. 3. W.R. Grace (GRA) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. 4. Abaxis (ABAX) downgraded to Neutral from Buy at Northcoast. 5. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing the stock's recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABUS Arbutus Biopharma
$2.65

-0.05 (-1.85%)

10/14/16
CHDN
10/14/16
UPGRADE
CHDN
Neutral
Arbutus Biopharma upgraded to Neutral from Sell at Chardan
10/14/16
10/14/16
UPGRADE

Neutral
Arbutus Biopharma upgraded to Neutral on valuation at Chardan
As previously reported, Chardan upgraded Arbutus Biopharma to Neutral from Sell. Analyst MadhuKumar upgraded shares citing relative shares underperformance ahead of Q4 and 2017 clinical catalyst in the Phase IIa study of ARB-1467.
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded to Buy from Neutral at Chardan

TODAY'S FREE FLY STORIES

SQ

Square

09:30
12/07/16
12/07
09:30
12/07/16
09:30
Hot Stocks
Square completes acquisition of Main Line Delivery; terms not disclosed »

Square said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDS

Precision Drilling

09:30
12/07/16
12/07
09:30
12/07/16
09:30
Upgrade
Precision Drilling rating change  »

Precision Drilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KTOV

Kitov Pharmaceuticals

$3.44

0.05 (1.47%)

09:27
12/07/16
12/07
09:27
12/07/16
09:27
Hot Stocks
Kitov Pharmaceuticals completes all KIT-302 testing to file NDA »

Kitov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$2.47

0.28 (12.79%)

09:25
12/07/16
12/07
09:25
12/07/16
09:25
Periodicals
Pioneer suspends a pair of senior Dublin execs, Irish Times reports »

UniCredit's Pioneer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARIA

ARIAD

$13.69

0.41 (3.09%)

09:25
12/07/16
12/07
09:25
12/07/16
09:25
Conference/Events
ARIAD to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 29

    Apr

OCLR

Oclaro

$8.35

-0.05 (-0.60%)

09:25
12/07/16
12/07
09:25
12/07/16
09:25
Conference/Events
Oclaro participates in a conference call with Jefferies »

Conference call with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:24
12/07/16
12/07
09:24
12/07/16
09:24
Hot Stocks
Starbucks says sees at-home coffee sales growth slowing »

Cites fewer Keurig sales.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

WDC

Western Digital

$63.85

1.76 (2.83%)

, SQ

Square

09:23
12/07/16
12/07
09:23
12/07/16
09:23
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Anthera…

WDC

Western Digital

$63.85

1.76 (2.83%)

SQ

Square

AAPL

Apple

$109.95

0.84 (0.77%)

PLAY

Dave & Buster's

$48.00

-0.83 (-1.70%)

VRA

Vera Bradley

$14.67

-0.07 (-0.47%)

ANTH

Anthera

$1.47

-0.03 (-2.00%)

SIGM

Sigma Designs

$7.75

0.1 (1.31%)

SSNLF

Samsung

AVAV

AeroVironment

$29.34

0.76 (2.66%)

OXM

Oxford Industries

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

  • 09

    Jan

  • 09

    Jan

  • 13

    Mar

WDAY

Workday

09:23
12/07/16
12/07
09:23
12/07/16
09:23
Downgrade
Workday rating change  »

Workday downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

AAPL

Apple

$109.95

0.84 (0.77%)

, GOOG

Alphabet

$759.11

-3.41 (-0.45%)

09:21
12/07/16
12/07
09:21
12/07/16
09:21
Hot Stocks
Kantar says Apple iOS share gains driven by iPhone 7 sales »

Kantar Worldpanel ComTech…

AAPL

Apple

$109.95

0.84 (0.77%)

GOOG

Alphabet

$759.11

-3.41 (-0.45%)

GOOGL

Alphabet Class A

$776.18

-2.04 (-0.26%)

MSFT

Microsoft

$59.95

-0.27 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 13

    Mar

AZO

AutoZone

09:20
12/07/16
12/07
09:20
12/07/16
09:20
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

AAPL

Apple

$109.95

0.84 (0.77%)

09:18
12/07/16
12/07
09:18
12/07/16
09:18
Downgrade
Apple rating change  »

Apple downgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:18
12/07/16
12/07
09:18
12/07/16
09:18
Hot Stocks
Starbucks says five-year goal is to 'elevate the brand' »

Also says goal is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NBR

Nabors Industries

09:16
12/07/16
12/07
09:16
12/07/16
09:16
Downgrade
Nabors Industries rating change  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

09:16
12/07/16
12/07
09:16
12/07/16
09:16
Hot Stocks
Fitbit acquires certain assets from Pebble, deal excludes hardware products »

Fitbit announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AVAV

AeroVironment

$29.34

0.76 (2.66%)

09:15
12/07/16
12/07
09:15
12/07/16
09:15
Hot Stocks
AeroVironment, Cal State Fresno to research water stress in almond trees »

AeroVironment announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
12/07/16
12/07
09:15
12/07/16
09:15
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

CLB

Core Laboratories

09:13
12/07/16
12/07
09:13
12/07/16
09:13
Downgrade
Core Laboratories rating change  »

Core Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ETFC

E-Trade

$35.52

0.31 (0.88%)

09:11
12/07/16
12/07
09:11
12/07/16
09:11
Hot Stocks
E-Trade CEO says running to grow company, not sell it »

Says running a company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:09
12/07/16
12/07
09:09
12/07/16
09:09
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

S

Sprint

$8.17

0.12 (1.49%)

09:08
12/07/16
12/07
09:08
12/07/16
09:08
Hot Stocks
Sprint becomes first U.S. Pokemon GO partner »

Sprint and Niantic,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Jan

RES

RPC, Inc.

$21.39

-0.24 (-1.11%)

09:08
12/07/16
12/07
09:08
12/07/16
09:08
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:07
12/07/16
12/07
09:07
12/07/16
09:07
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts hold an…

HBAN

Huntington Bancshares

$13.22

0.19 (1.46%)

09:07
12/07/16
12/07
09:07
12/07/16
09:07
Hot Stocks
Huntington Bancshares sees FY17 revenue growth of 20%+ »

Says implementation of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OCRX

Ocera Therapeutics

$2.35

0.1 (4.44%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Hot Stocks
Ocera Therapeutics completes enrollment in STOP-HE Phase 2b study »

Ocera Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.